Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2011 Aug 24;18(4):640–647. doi: 10.1016/j.bbmt.2011.08.012

Figure 3.

Figure 3

Kaplan-Meier estimates of: A) Overall Survival from time of relapse, stratified by length of time between HD-ASCT and relapse (n=51 relapses, n=6 TRM excluded), log-rank p<0.001; and B) Overall Survival from time of relapse for those that relapsed 1–3 years post HD-ASCT versus those that relapsed >3 years post HD-ASCT (n=26), log-rank p=0.93, Hazard Ratio for OS with relapse >3 years post HD-ASCT vs. OS with relapse 1–3 years post HD-ASCT = 1.05 (95% CI: 0.39–2.77).